Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | GRIN1 | Q05586 | 10/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6224523 | 0.92 | ALDH1A1 (0.56) | ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1945404 | 0.79 | ALDH1A1 (1.00) | ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4043882 | 0.76 | ALDH1A1 (0.66) | ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5397566 | 0.74 | ALDH1A1 (0.46) | ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10735070 | 0.72 | KMT2A (0.85) | ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1545981 | 0.69 | MEN1 (0.61) | ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1959768 | 0.68 | ALDH1A1 (0.73) | ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6014099 | 0.65 | MEN1 (0.51) | ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1943792 | 0.64 | ALDH1A1 (0.54) | ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1546788 | 0.64 | ALDH1A1 (0.54) | ALDH1A1CYP3A4MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664052-B1 | FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-7371757-B2 | Fused heterocycles as inhibitors of glutamate racemase(MURI) | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| US-20070004761-A1 | Pyrazolo [3,4-d] pyrimidine derivatives and their use in the treatment of h.pylori infection | HETERO DRUGS LIMITED (IN) | 2007-01-04 | — | — | US | disclosed |
| EP-1585748-B1 | PYRAZOLO 3,4-d PYRIMIDINE DERIVATIVES AND THEIR USE I N THE TREATMENT OF H.PYLORI INFECTION | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| US-20060252781-A1 | Fused heterocycles as inhibitors of glutamate racemase(muri) | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | US | disclosed |
| EP-1664052-A1 | FUSED HETEROCYCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1585748-A1 | PYRAZOLO 3,4-d PYRIMIDINE DERIVATIVES AND THEIR USE I N THE TREATMENT OF H.PYLORI INFECTION | AstraZeneca AB (SE) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005016929-A1 | FUSED HETEROCYLCLES AS INHIBITORS OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004056831-A1 | PYRAZOLO [3,4-d] PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF H.PYLORI INFECTION | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004761-A1 | Pyrazolo [3,4-d] pyrimidine derivatives and their use in the treatment of h.pylori infection | DPYD, TPMT, UMPS | ALDH1A1 1865/4885CYP3A4 207/4885MEN1 4608/4885 |
| US-20060252781-A1 | Fused heterocycles as inhibitors of glutamate racemase(muri) | GLUL, RIMKLA, GGH | ALDH1A1 1068/4885CYP3A4 2539/4885MEN1 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.